A medical device, developed by Lenexa Medical for Pressure injury (PI) prevention, has been approved for sale in New Zealand. LenexaCARE which was also recently listed on the Australian Register of Therapeutic Goods (ARTG), and is currently being trialed in Australian hospitals, is based on a sensor array embedded in the surface fabric of a bed mattress which assists clinicians in preventing pressure injuries by providing real time monitoring for patient positioning.
Pressure injuries are mostly preventable. However, they remain a devastating complication, for patients in hospital and aged care settings, particularly where a person is immobile for a prolonged period. When a pressure injury advances to a deep wound, it can become life threatening. This issue has been further exacerbated by the COVID-19 pandemic, and affects 55,000 people in NZ and estimated to cost the NZ healthcare system upwards of $700 million annually.
“LenexaCARE provides ongoing monitoring and can alert clinicians and carers to problems before they are even detected by the human eye,” explained Ajit Ravindran, CEO of Lenexa Medical.
“Pressure injuries are a worldwide issue and Lenexa Medical is thrilled to make LenexaCARE available in New Zealand and support the clinicians and patients who are dealing with this costly and preventable issue.”
“We’re passionate about change in health and actually making a difference,” said Gavin Bunshaw, CEO at DB Results a global digital business that has helped bring the product to market.
“In terms of a breakthrough the technology can be used for other uses down the track, but if we can solve pressure injuries and then look at using it usefully in aged care and also home care, I actually think it will lead the way in terms of providing that remote monitoring.”
For further information visit here.
